104037-38-9

Usage

Uses

Since the specific properties and uses of RARECHEM AN KA 0422 are not provided in the materials, it is not possible to list its applications in different industries or as different application types. However, it is essential to consider the potential applications of the compound based on its chemical properties and the industry it is intended for. Once more information is available, the uses of RARECHEM AN KA 0422 can be better understood and listed accordingly.

Upstream product

• 1011-50-3 2-quinolin-2-yl-ethanol 
• 74273-98-6 N-<2-(2-Quinolyl)ethyl>succinimide 
• 14068-28-1 2-(quinolin-2-yl)acetonitrile 
• 2005-43-8 2-bromoquinoline 
• 85454-13-3 2-(2-chloroethyl)quinoline 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 4377-41-7 2-Chloromethylquinoline 
• 5100-57-2 ethyl 2-(2-quinolyl)acetate 

Downstream Products

• 757249-10-8 N-(2-[2]quinolyl-ethyl)-formamide 
• 1628618-33-6 7-chloro-5-methyl-2-(2-quinolin-2-ylethyl)-3,5-dihydro-2H-pyrrolo[3,4-c]pyridine-1,6-dione 

Relevant academic research and scientific papers

Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors

Pulmonary arterial hypertension (PAH) causes pathological increase in pulmonary vascular resistance, leading to right-heart failure and eventual death. Previously, phosphodiesterase-10 (PDE10) was reported to be a promising target for PAH based on the studies with a nonselective PDE inhibitor papaverine, but little progress has been made to confirm the practical application of PDE10 inhibitors. To validate whether PAH is ameliorated by PDE10 inhibition rather than other PDE isoforms, here we report an integrated strategy to discover highly selective PDE10 inhibitors as chemical probes. Structural optimization resulted in a PDE10 inhibitor 2b with subnanomolar affinity and good selectivity of >45 000-fold against other PDEs. The cocrystal structure of the PDE10-2b complex revealed an important H-bond interaction between 2b and Tyr693. Finally, compound 2b significantly decreased the arterial pressure in PAH rats and thus validated the potential of PDE10 as a novel anti-PAH target. These findings suggest that PDE10 inhibition may be a viable treatment option for PAH.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders